127
Participants
Start Date
September 23, 2011
Primary Completion Date
April 3, 2017
Study Completion Date
April 3, 2017
Eribulin
1.4 mg/m\^2 IV Days 1 and 8, every 21 days for six cycles
Trastuzumab
6 mg/kg IV Day 1 every 21 days
Center for Cancer and Blood Disorders, Bethesda
National Capital Clinical Research Consortium, Bethesda
South Carolina Oncology Associates, Columbia
Northeast Georgia Medical Center, Gainesville
Florida Hospital Cancer Insitute, Orlando
Watson Clinic Center for Cancer Care and Research, Lakeland
Florida Cancer Specialists North, Fort Myers
Florida Cancer Specialists South, Fort Myers
Tennessee Oncology, Nashville
Chattanooga Oncology Hematology Associates, Chattanooga
Oncology Hematology Care, Inc., Cincinnati
Providence Medical Group, Terre Haute
Nebraska Methodist Cancer Center, Omaha
Texas Health Physician Group, Arlington
The Center for Cancer and Blood Disorders, Fort Worth
Mercy Hospital, Portland
Atlantic Health System, Morristown
Hematology Oncology Associates of Northern NJ, Morristown
Eisai Inc.
INDUSTRY
SCRI Development Innovations, LLC
OTHER